We are live on
!
Find out more
SGAM
Smith Group Asset Management Portfolio holdings
AUM
$2.46B
1-Year Est. Return
57.16%
This Fund
S&P 500
This Quarter
Est. Return
+31.89%
1 Year Est. Return
+57.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
-$18.2M
(-0.99%)
Cap. Flow
-$444M
Cap. Flow
% of AUM
-24.46%
Top 10 Holdings %
Top 10 Hldgs %
40.04%
Holding
396
New
38
Increased
53
Reduced
183
Closed
98
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$24.1M |
| 2 |
Parker-Hannifin
PH
|
+$20.9M |
| 3 |
Ameriprise Financial
AMP
|
+$15.8M |
| 4 |
THS
Treehouse Foods
THS
|
+$12.2M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$12.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$48.5M |
| 2 |
Microsoft
MSFT
|
+$45.5M |
| 3 |
Biogen
BIIB
|
+$36M |
| 4 |
Amazon
AMZN
|
+$29.7M |
| 5 |
Burlington
BURL
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.49% |
| 2 | Healthcare | 16.85% |
| 3 | Consumer Discretionary | 12.94% |
| 4 | Communication Services | 8.43% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Xencor
XNCR
$1.6B
| $57K | ﹤0.01% |
1,760
-4,405
| -71% | -$135K |
|
202
TotalEnergies
TTE
$195B
| $50K | ﹤0.01% |
1,306
+210
| +19% | +$7.78K |
|
203
Bank of America
BAC
$447B
| $49K | ﹤0.01% |
2,045
-805,793
| -100% | -$19M |
|
|
ICPT
204
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $49K | ﹤0.01% |
1,030
-20
| -2% | -$1.54K |
|
|
ALLK
205
DELISTED
Allakos
ALLK
| $47K | ﹤0.01% |
650
-10
| -2% | -$670 |
|
206
Citigroup
C
$227B
| $43K | ﹤0.01% |
840
+2
| +0.2% | +$95 |
|
207
Ironwood Pharmaceuticals
IRWD
$669M
| $43K | ﹤0.01% |
4,140
-30
| -0.7% | -$307 |
|
|
CEO
208
DELISTED
CNOOC Limited
CEO
| $43K | ﹤0.01% |
377
+60
| +19% | +$6.78K |
|
209
Regenxbio
RGNX
$688M
| $42K | ﹤0.01% |
1,140
-20
| -2% | -$746 |
|
210
DuPont de Nemours
DD
$19.1B
| $41K | ﹤0.01% |
614
+105
| +21% | +$6.13K |
|
211
Heron Therapeutics
HRTX
$63.4M
| $41K | ﹤0.01% |
2,810
-30
| -1% | -$493 |
|
212
Wells Fargo
WFC
$265B
| $40K | ﹤0.01% |
1,561
+300
| +24% | +$8.21K |
|
213
Blackrock
BLK
$175B
| $39K | ﹤0.01% |
71
+2
| +3% | +$1.01K |
|
214
Allstate
ALL
$68.2B
| $36K | ﹤0.01% |
367
-5
| -1% | -$491 |
|
215
Enanta Pharmaceuticals
ENTA
$402M
| $36K | ﹤0.01% |
720
-20
| -3% | -$1.03K |
|
216
Linde
LIN
$227B
| $36K | ﹤0.01% |
169
+110
| +186% | +$21.2K |
|
217
US Bancorp
USB
$100B
| $36K | ﹤0.01% |
987
-5
| -0.5% | -$178 |
|
218
ENI
E
$79.4B
| $35K | ﹤0.01% |
1,796
+300
| +20% | +$5.77K |
|
219
Enbridge
ENB
$112B
| $35K | ﹤0.01% |
1,143
+190
| +20% | +$5.84K |
|
|
PTLA
220
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $35K | ﹤0.01% |
1,970
-20
| -1% | -$278 |
|
221
Dow Inc
DOW
$22.1B
| $34K | ﹤0.01% |
830
+130
| +19% | +$4.76K |
|
222
PNC Financial Services
PNC
$100B
| $34K | ﹤0.01% |
322
-5
| -2% | -$527 |
|
223
LyondellBasell Industries
LYB
$20.2B
| $33K | ﹤0.01% |
507
+130
| +34% | +$7.74K |
|
224
Morgan Stanley
MS
$338B
| $31K | ﹤0.01% |
639
-20
| -3% | -$840 |
|
|
RDS.B
225
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $31K | ﹤0.01% |
1,002
+160
| +19% | +$5.23K |
|
Similar funds
M
GWM
QT
SCM
TW
KFA
SG
FFA
Smith Group Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, Smith Group Asset Management held 396 positions worth $1.81B, down 0.99% from $1.83B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Smith Group Asset Management withdrew a net $444M in Q2 2020, closing 98 positions and reducing 183 holdings. Its most notable exit was Biogen, an estimated $36M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 37% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Smith Group Asset Management opened a new position in Hologic worth $28M.
- Smith Group Asset Management's largest Q2 2020 buy was Hologic: 490,762 shares worth $28M.
- Smith Group Asset Management added most to Ameriprise Financial in Q2 2020, an estimated $15.8M increase.
- Smith Group Asset Management's biggest Q2 2020 reduction was Apple, cutting an estimated $48.5M.
- Smith Group Asset Management fully exited Biogen in Q2 2020, selling an estimated $36M.
- Smith Group Asset Management's ten largest holdings make up 40% of its $1.81B portfolio in Q2 2020.
- Smith Group Asset Management opened 38 new positions and closed 98 in Q2 2020.
- Smith Group Asset Management's portfolio value fell 0.99% quarter-over-quarter to $1.81B.
Based on Smith Group Asset Management's 13F filing for Q2 2020, filed 6 Aug 2020.